JP2004523538A5 - - Google Patents

Download PDF

Info

Publication number
JP2004523538A5
JP2004523538A5 JP2002562389A JP2002562389A JP2004523538A5 JP 2004523538 A5 JP2004523538 A5 JP 2004523538A5 JP 2002562389 A JP2002562389 A JP 2002562389A JP 2002562389 A JP2002562389 A JP 2002562389A JP 2004523538 A5 JP2004523538 A5 JP 2004523538A5
Authority
JP
Japan
Prior art keywords
antibody
therapeutic agent
agent according
ischemic stroke
humans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002562389A
Other languages
English (en)
Japanese (ja)
Other versions
JP5005156B2 (ja
JP2004523538A (ja
Filing date
Publication date
Priority claimed from GBGB0103174.9A external-priority patent/GB0103174D0/en
Application filed filed Critical
Publication of JP2004523538A publication Critical patent/JP2004523538A/ja
Publication of JP2004523538A5 publication Critical patent/JP2004523538A5/ja
Application granted granted Critical
Publication of JP5005156B2 publication Critical patent/JP5005156B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002562389A 2001-02-08 2002-02-08 新規治療方法 Expired - Fee Related JP5005156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0103174.9A GB0103174D0 (en) 2001-02-08 2001-02-08 Novel method of treatment
GB0103174.9 2001-02-08
PCT/GB2002/000551 WO2002062383A2 (en) 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008137916A Division JP2008291031A (ja) 2001-02-08 2008-05-27 新規治療方法

Publications (3)

Publication Number Publication Date
JP2004523538A JP2004523538A (ja) 2004-08-05
JP2004523538A5 true JP2004523538A5 (enExample) 2005-12-22
JP5005156B2 JP5005156B2 (ja) 2012-08-22

Family

ID=9908386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002562389A Expired - Fee Related JP5005156B2 (ja) 2001-02-08 2002-02-08 新規治療方法
JP2008137916A Ceased JP2008291031A (ja) 2001-02-08 2008-05-27 新規治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008137916A Ceased JP2008291031A (ja) 2001-02-08 2008-05-27 新規治療方法

Country Status (11)

Country Link
US (2) US20040170627A1 (enExample)
EP (2) EP1645285A3 (enExample)
JP (2) JP5005156B2 (enExample)
AT (1) ATE314861T1 (enExample)
AU (1) AU2002229928A1 (enExample)
CY (1) CY1105549T1 (enExample)
DE (1) DE60208534T2 (enExample)
DK (1) DK1357941T3 (enExample)
ES (1) ES2254655T3 (enExample)
GB (1) GB0103174D0 (enExample)
WO (1) WO2002062383A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA05012307A (es) * 2003-05-16 2006-07-03 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
JP2007521248A (ja) * 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
CA2623635C (en) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
JP4841017B2 (ja) * 1995-06-27 2011-12-21 リサーチ ファウンデーション オブ シーユーエヌワイ， ハンター カレッジ ミエリン会合糖タンパク質（ｍａｇ）およびそのインヒビターを用いた組成物および方法
DE69818106T2 (de) * 1997-10-28 2004-06-17 The University Of British Columbia, Vancouver Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
WO1999053945A1 (en) * 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Similar Documents

Publication Publication Date Title
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
JP2019518742A5 (enExample)
JP2022031635A5 (enExample)
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
JP2007051159A5 (enExample)
JP2008538564A5 (enExample)
DE60042648D1 (de) Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
DE05075555T1 (de) Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
JP2004523538A5 (enExample)
ATE181575T1 (de) Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
ATE557042T1 (de) Anti-myostatin-antikörper
PE20160999A1 (es) Metodos para administrar anticuerpos anti-tnf-alfa
JP2002506648A5 (enExample)
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
JP2004532885A5 (enExample)
JP2020508074A5 (enExample)
JP2004508415A5 (enExample)
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.